Frontlight ResearchEarly access
Liver cirrhosis trials in Belgium
8 of 16 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Where
- Brussels, Edegem
- Age
- 18 years to 80 years
- People
- 2,150 worldwide
- Run by
- Akero Therapeutics, Inc
See details and how to joinNCT06528314 - Phase 3Taking peopleLIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- Where
- Anderlecht, Edegem, Genk, Liège
- Age
- 18 years and over
- People
- 1,590 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632457 · EU 2024-513741-36-00 - Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- Where
- Anderlecht, Edegem, Genk, Gent, Jette, Roeselare, Sint-Lambrechts-Woluwe
- Age
- 18 years to 75 years
- People
- 1,800 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06419374 · EU 2023-510395-31-00 - No phaseTaking peopleEUS-guided Response Assessment to NSBB
- Where
- Leuven
- Age
- 18 years to 80 years
- People
- 24
- Run by
- Universitaire Ziekenhuizen KU Leuven
See details and how to joinNCT06513195 - Phase 3Taking peoplePersonalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites
- Where
- Leuven
- Age
- 18 years and over
- People
- 240 worldwide
- Run by
- Aleksander Krag
See details and how to joinNCT05056220 - Phase 3Active, not recruitingAn European multinational study of a personalized approach of human albumin administration in patients with cirrhosis of the liver and complications
- Where
- Leuven
- Age
- 18 years and over
- People
- 200 worldwide
- Run by
- Odense University Hospital
See details and how to join2022-501006-34-01 - Phase 1Not yet taking people in BelgiumA study to evaluate the safety and tolerability of single ascending doses of AGMB-101 in healthy participants (Part A) and patients with liver cirrhosis (Part B).
- Where
- Edegem
- Age
- 18 years and over
- People
- 64
- Run by
- AgomAb Therapeutics
See details and how to join2024-515074-26-00 - Phase 4Taking peoplePrevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose
- Where
- Edegem, Leuven
- Age
- 18 years to 80 years
- People
- 238 worldwide
- Run by
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
See details and how to joinNCT04073290 · EU 2024-512040-28-01